The objective of the present study was to measure circulating levels of Lp(a), Apo CIII, ANGPTL3 and PCSK9 in women diagnosed either with a high-grade serous ovarian carcinoma (HGSOC) or a benign ovarian lesion (BOL), given the availability of monoclonal antibodies and antisense therapy targeting these lipid-related factors. This evidence concerns the gene APOC3 and ovarian serous carcinoma.